Clinical Trial Update: Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation [Phase 1]

View source ↗

Summary

A Phase I trial evaluating HSK42360 for malignant brain tumors with BRAF V600 mutation is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor

Drugs mentioned

• HSK42360

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Malignant Brain Tumors | Phase 1 | Status: RECRUITING